Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.98

+1.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: A.J. Mullen	6/13/2023 7:08:45 PM
	of 52153

Good news/ bad news (or the reverse for some) from ft.com. The good news is that M&A activity in Pharma has recovered - fueled by large cash troves and a wave patent exclusivity ending. The bad news is the FTC is newly active in scrutinizing deals. It warned that rampant consolidation was pushing up prices. It sued to block Amgen from an acquisition. (It also looks as if Illumina is going to divest itself of Grail at least in part because of opposition from the UK and US regulatory bodies.) Industry insiders are arguing the FTC doesn't understand the fundamental business model of Pharma that is the engine of development. One analyst predicted interest in megadeals would thaw and switch to earlier-stage companies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next